DEA Reclassifies Plant-Derived Marijuana Medicine to Schedule V | NORML
Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified today by the US Drug Enforcement Administration to Schedule V — the lowest restriction classification available under federal law. The US Food and Drug Administration had previously approved the product in June for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. It […]
DEA Reclassifies Plant-Derived Marijuana Medicine to Schedule V | The Daily Chronic
http://www.thedailychronic.net/2018/91817/dea-reclassifies-plant-derived-marijuana-medicine-schedule-v/
